Status:
COMPLETED
Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
Lymphopenia
Covid19
Eligibility:
All Genders
70+ years
Brief Summary
Background: Lymphopenia is reported to be associated with the severity of disease progression in COVID-19. Low lymphocyte count is also associated with increasing age. No study has yet investigated th...
Detailed Description
Introduction In December 2019 a cluster of viral pneumonia cases in Wuhan, a city in the Hubei Province of China, led to the discovery of a novel pathogen that was later named Severe Acute Respiratory...
Eligibility Criteria
Inclusion
- Cfr definition of the three groups
Exclusion
- Patients receiving immunosuppressive therapy, patients with known active cancer or hematologic disorders, patients undergoing radio- or chemotherapy or with known autoimmune diseases will not be included since these underlying conditions or therapies can interfere with white blood cell count in a way that is beyond the scope of this research.
Key Trial Info
Start Date :
June 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
227 Patients enrolled
Trial Details
Trial ID
NCT04800731
Start Date
June 30 2021
End Date
June 30 2022
Last Update
January 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ brussel
Brussels, Belgium, 1090